Newtyn Management’s TScan Therapeutics TCRX Stock Holding History

Newtyn Management’s Portfolio TCRX Stock Details TCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-236,800	Closed	-$497K	–	74
2023 Q1	$497K	Buy	236,800 +6,800	+3%	+$16.1K	0.1%	70
2022 Q4	$375K	Buy	230,000 +30,000	+15%	+$73.6K	0.08%	65
2022 Q3	$610K	Sell	200,000 -48,611	-20%	-$159K	0.13%	63
2022 Q2	$782K	Buy	+248,611	New	+$680K	0.15%	65

Other funds holding TCRX

LCM

Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

DMC

Deer Management Company Larchmont, New York $622M AUM 24.27% 1-Year Est. Return

Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return

SAM

Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return

Newtyn Management's TCRX Position: Q2 2023 in Review

Newtyn Management sold out of TScan Therapeutics (TCRX) in Q2 2023, closing a stake of 236,800 shares — an estimated $497K sold.

Newtyn Management first reported a position in TCRX in Q2 2022 and held it in 4 quarters. The position peaked at $782K in Q2 2022. 28 funds tracked by Wall St. Rank hold TCRX as of Q2 2023.

Newtyn Management reported no remaining TScan Therapeutics position as of Q2 2023 after selling out during the quarter.
Newtyn Management sold 236,800 TScan Therapeutics shares in Q2 2023, an estimated $497K.
Newtyn Management first reported a position in TScan Therapeutics in Q2 2022 and held it in 4 quarters.
Newtyn Management's TScan Therapeutics position peaked at $782K in Q2 2022.
28 funds tracked by Wall St. Rank held TScan Therapeutics as of Q2 2023.

Based on Newtyn Management's 13F filing for Q2 2023, filed 14 Aug 2023.